Want to see HK:6990 full AI Analyst Report?
6990 Stock Chart & Stats
HK$520.00
-HK$6.30(-3.77%)
At close: 4:00 PM EST
HK$520.00
-HK$6.30(-3.77%)
Day’s Range― - ―
52-Week RangeHK$339.60 - HK$581.00
Previous CloseN/A
Volume210.00K
Average Volume (3M)641.47K
Market Cap
HK$129.18B
Enterprise ValueHK$8.76B
Total Cash (Recent Filing)HK$4.56B
Total Debt (Recent Filing)HK$88.44M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Aug 24, 2026EPS Estimate
0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.80
Shares Outstanding176,822,250
10 Day Avg. Volume649,182
30 Day Avg. Volume641,465
Financial Highlights & Ratios
PEG Ratio-5.55
Price to Book (P/B)16.74
Price to Sales (P/S)39.59
P/FCF Ratio-265.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$561.61Price Target Upside8.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.56
Revenue Forecast (FY)HK$2.79B
Bulls Say, Bears Say
Bulls Say
Commercialization StrategySignificant strides in commercialization with three commercialized assets and plans to expand the commercial team to over 500 employees.
Financial PerformanceKelun-Biotech reported strong financial results, driven by milestone payments from global collaborations and the progression of its innovative pipeline.
Innovation In Drug DevelopmentKelun-Biotech is advancing a multi-pronged ADC strategy across oncology and non-oncology, leveraging novel payloads and next-generation conjugation technologies.
Strategic PartnershipsLicensing and collaboration agreements contributed RMB 1.86bn revenue, reflecting strong partnerships with milestone payments from MSD.
Bears Say
Licensing ConcernsDespite successful out-licensing of SKB378, the significant valuation of up to US$970 million plus royalties may raise concerns about market expectations.
Net LossThe Company narrowed its net loss significantly to RMB 266.8mn, though still operating at a loss despite revenue growth outpacing cost expansion.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H News
6990 FAQ
What was Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s price range in the past 12 months?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H lowest stock price was HK$339.60 and its highest was HK$581.00 in the past 12 months.
What is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s market cap?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s market cap is HK$129.18B.
When is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s upcoming earnings report date?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s upcoming earnings report date is Aug 24, 2026 which is in 37 days.
How were Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s earnings last quarter?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H released its earnings results on Mar 23, 2026. The company reported -HK$1.049 earnings per share for the quarter, beating the consensus estimate of -HK$1.542 by HK$0.493.
Is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H overvalued?
According to Wall Street analysts Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s price is currently Undervalued.
Does Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H pay dividends?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H does not currently pay dividends.
What is Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s EPS estimate?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s EPS estimate is 0.27.
How many shares outstanding does Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H have?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H has 176,822,250 shares outstanding.
What happened to Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H’s price movement after its last earnings report?
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H reported an EPS of -HK$1.049 in its last earnings report, beating expectations of -HK$1.542. Following the earnings report the stock price went down -4.789%.
Which hedge fund is a major shareholder of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6990
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$561.61 (8.00% Upside)
HK$561.61 (8.00% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
148.29%
12-Months-Change
Fundamentals
Return on Equity
-8.96%
Trailing 12-Months
Asset Growth
46.85%
Trailing 12-Months
Company Description
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas in the People’s Republic of China and internationally. The company’s product pipeline includes Sac-TMT, a novel TROP2 ADC positioned as a monotherapy and part of combination therapies for treating various advanced solid tumors; Trastuzumab botidotin, a monotherapy to treat advanced HER2+ solid tumors; SKB315, a novel CLDN18.2 ADC targeting advanced solid tumors; SKB410/MK-3120, a novel Nectin-4 ADC targeting advanced solid tumors; and SKB571/MK-2750, a novel bsADC primarily targeting various solid tumors, such as LC and CRC. The company also develops SKB518, SKB535/MK-6204 and SKB445, which are novel ADC drugs with potential FIC targets; SKB500 and SKB501, which are novel ADC drugs with verified targets but differentiated payload-linker strategies; SKB107, an RDC targeting tumor bone metastases; Tagitanlimab, PD-L1 mAb for its immunotherapy franchise; Cetuximab N01, a recombinant EGFR human-mouse chimeric mAb; A400, a novel selective RET inhibitor; and A296, a novel small molecule STING agonist. It has license and collaboration arrangements with Merck Sharp & Dohme LLC; Harbour BioMed Therapeutics Limited; Windward Bio AG; and Ellipses Pharma Limited. The company has a strategic partnership with Crescent Biopharma, Inc. The company was incorporated in 2016 and is headquartered in Chengdu, the People’s Republic of China. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (6990) Earnings & Revenues
6990 Stock 12 Month Forecast
Average Price Target
HK$561.61
▲(8.00% Upside)
Technical Analysis
Innovent Biologics
―
Wuxi Biologics (Cayman)
―
Akeso, Inc.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―